RegulatoryAug 4, 2026, 05:17 AM
CervoMed's Neflamapimod Gets UK Innovation Passport for DLB
AI Summary
CervoMed Inc. announced that its drug candidate, neflamapimod, has been granted an Innovation Passport to enter the UK's Innovative Licensing and Access Pathway (ILAP) for its development in Dementia with Lewy Bodies (DLB). This designation is designed to accelerate time to market and facilitate patient access to potentially transformative new investigational medicines by providing early and coordinated guidance from UK regulatory and health bodies. The company is preparing for a planned Phase 3 trial for neflamapimod in DLB, building on positive results from previous Phase 2 trials.
Key Highlights
- Neflamapimod granted UK Innovation Passport for DLB.
- Entry into UK's Innovative Licensing and Access Pathway (ILAP).
- ILAP designed to accelerate market access for new medicines.
- Provides coordinated guidance from MHRA, NHS, and HTA bodies.
- Neflamapimod targets neuroinflammation in degenerative brain disorders.
- Company plans for a Phase 3 trial for neflamapimod in DLB.
- Demonstrated efficacy in Phase 2a AscenD-LB and Phase 2b RewinD-LB trials.
- Currently in Phase 2a for nfvPPA and Phase 2a EXPERTS-ALS.
Price Impact
More from CRVO